Company intelligence / Profile preview

Purespring Therapeutics

London, England, United Kingdompurespringtx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Purespring has demonstrated in preclinical studies that its lead program PS-002 reduced signs of kidney dysfunction, lowered complement deposition, and ameliorated kidney scarring in mouse models of IgAN. In pigs, treatment resulted in elevated and prolonged gene expression in kidney tissues with no safety issues. The company is preparing to initiate a Phase I/II clinical trial for IgAN.

Therapeutic areas: Nephrology
Modalities: AAV gene therapy
Industry: Biotech

Drug pipeline

3 assets

PS-001

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Purespring Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Purespring Therapeutics.

Explore the full profile